Zobrazeno 1 - 10
of 2 141
pro vyhledávání: '"dpp-4 inhibitor"'
Autor:
Abdul Samad, Sammia Shahid, Sana Mansoor, Sehrish Afzal, Mohsin Javed, Ammar Zidan, Abdullah Shoaib, Fadi Jaber, Shahid Iqbal, Muhammad Saad, Sajid Mahmood, Nasser S. Awwad, Hala A. Ibrahium
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Diabetes mellitus (DM) is a rapidly prevailing disease throughout the world that poses boundless risk factors linked to several health problems. Vildagliptin is the standard dipeptidyl peptidase-4 (DPP-4) inhibitor type of medication that is
Externí odkaz:
https://doaj.org/article/d76409734d4d46dc9ce2d64bc3fcf3aa
Autor:
Masashi Shimoda, Yukino Katakura, Akiko Mashiko, Masahiro Iwamoto, Shuhei Nakanishi, Takatoshi Anno, Fumiko Kawasaki, Atsushi Obata, Yoshiro Fushimi, Junpei Sanada, Kenji Kohara, Hayato Isobe, Yuichiro Iwamoto, Hidenori Hirukawa, Fuminori Tatsumi, Yukiko Kimura, Tomohiko Kimura, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
AimsThe aim of this study is to directly compare the effects of SGLT2 inhibitors and DPP-4 inhibitors on β-cell function in patients with type 2 diabetes.Materials and methodsWe conducted a 26-week, randomized, open-label, parallel-group study, incl
Externí odkaz:
https://doaj.org/article/214b5df748a049da953de0bc203a615c
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 178, Iss , Pp 117179- (2024)
Diabetes, a metabolic disease caused by abnormally high levels of blood glucose, has a high prevalence rate worldwide and causes a series of complications, including coronary heart disease, stroke, peripheral vascular disease, end-stage renal disease
Externí odkaz:
https://doaj.org/article/1218c7ce7bcd4136a0ec5f6fae92596a
Autor:
Dwight D. Harris, Sharif A. Sabe, Mark Broadwin, Krishna Bellam, Cynthia M. Xu, Janelle W. Li, M. Ruhul Abid, Frank W. Sellke
Publikováno v:
Physiological Reports, Vol 12, Iss 5, Pp n/a-n/a (2024)
Abstract Small animal models have shown improved cardiac function with DPP‐4 inhibition, but many human studies have shown worse outcomes or no benefit. We seek to bridge the gap by studying the DPP‐4 inhibitor sitagliptin in a swine model of chr
Externí odkaz:
https://doaj.org/article/f27f84df195941149f8e675d33ffaaac
Publikováno v:
Journal of Diabetes Investigation, Vol 14, Iss 6, Pp 756-766 (2023)
ABSTRACT Aims/Introduction Although the association between dipeptidyl peptidase‐4 (DPP‐4) inhibitors and bullous pemphigoid (BP) has begun to be established, some studies have suggested there are risk differences among DPP‐4 inhibitors. We con
Externí odkaz:
https://doaj.org/article/5e5db9e0965b4cdfb5d24f334d70d517
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 32, Iss , Pp 101957- (2023)
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old
Externí odkaz:
https://doaj.org/article/59edd01299f947d8988f8ff112966b81
Publikováno v:
Molecular Metabolism, Vol 78, Iss , Pp 101806- (2023)
Objective: Abnormal autophagic function and activated inflammasomes are typical features in the liver of patients with non-alcoholic steatohepatitis (NASH). Here, we explored whether gemigliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor for treatmen
Externí odkaz:
https://doaj.org/article/d488041489a1447d94648f8e507925b7
Autor:
Akashi N, Umemoto T, Yamada H, Fujiwara T, Yamamoto K, Taniguchi Y, Sakakura K, Wada H, Momomura SI, Fujita H
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 16, Pp 1043-1054 (2023)
Naoyuki Akashi,1 Tomio Umemoto,1 Hodaka Yamada,2 Takayuki Fujiwara,3 Kei Yamamoto,1 Yousuke Taniguchi,1 Kenichi Sakakura,1 Hiroshi Wada,1 Shin-ichi Momomura,1 Hideo Fujita1 1Division of Cardiovascular Medicine, Jichi Medical University Saitama Medica
Externí odkaz:
https://doaj.org/article/309ee3f6d99f438897e285be8a9d6247
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 16, Pp 4301-4310 (2022)
Yesong Shin,1 Chungam Choi,2 Eun Sil Oh,2,3 Choon Ok Kim,2 Kyungsoo Park,1 Min Soo Park2– 4 1Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea; 2Department of Clinical Pharmacology and Clinical Trials Center, Severance
Externí odkaz:
https://doaj.org/article/edcb8ab1ea8c467c9a6f2027e443d253
Publikováno v:
Acta Biochimica et Biophysica Sinica, Vol 54, Pp 1406-1420 (2022)
The role of gut-kidney crosstalk in the progression of diabetic nephropathy (DN) is receiving increasing concern. On one hand, the decline in renal function increases circulating uremic toxins and affects the composition and function of gut microbiot
Externí odkaz:
https://doaj.org/article/dc7b65bcd1474b43bd20fbad5186e710